 Peter Mourani
Concepts (448)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 23 | 2021 | 325 | 5.260 |
Why?
| | Intensive Care Units, Pediatric | 26 | 2023 | 157 | 3.010 |
Why?
| | Cardiopulmonary Resuscitation | 14 | 2023 | 224 | 2.510 |
Why?
| | Heart Arrest | 15 | 2023 | 291 | 2.480 |
Why?
| | Respiration, Artificial | 17 | 2023 | 543 | 2.240 |
Why?
| | Infant, Premature | 17 | 2021 | 479 | 2.130 |
Why?
| | Hypertension, Pulmonary | 13 | 2023 | 1784 | 2.090 |
Why?
| | Pneumonia, Ventilator-Associated | 3 | 2021 | 41 | 2.030 |
Why?
| | Critical Illness | 22 | 2024 | 661 | 1.970 |
Why?
| | Microbiota | 8 | 2024 | 655 | 1.940 |
Why?
| | Shock, Septic | 11 | 2023 | 187 | 1.890 |
Why?
| | Sepsis | 12 | 2023 | 531 | 1.530 |
Why?
| | Trachea | 3 | 2017 | 225 | 1.410 |
Why?
| | Respiratory Insufficiency | 5 | 2021 | 289 | 1.410 |
Why?
| | Respiratory Tract Infections | 5 | 2024 | 329 | 1.350 |
Why?
| | Infant, Newborn | 39 | 2022 | 5230 | 1.300 |
Why?
| | Child | 83 | 2024 | 19033 | 1.300 |
Why?
| | Prospective Studies | 40 | 2023 | 6443 | 1.240 |
Why?
| | Vascular Diseases | 5 | 2020 | 241 | 1.160 |
Why?
| | Critical Care | 6 | 2021 | 488 | 1.100 |
Why?
| | Premature Birth | 4 | 2021 | 284 | 1.070 |
Why?
| | Echocardiography | 7 | 2021 | 556 | 0.970 |
Why?
| | Infant | 41 | 2023 | 8254 | 0.960 |
Why?
| | Lung | 9 | 2024 | 3623 | 0.950 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2022 | 232 | 0.930 |
Why?
| | Influenza, Human | 9 | 2023 | 553 | 0.910 |
Why?
| | Heart Ventricles | 2 | 2021 | 725 | 0.900 |
Why?
| | Intensive Care Units | 9 | 2023 | 633 | 0.880 |
Why?
| | Humans | 121 | 2024 | 118268 | 0.850 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2021 | 507 | 0.830 |
Why?
| | Ventricular Function, Right | 2 | 2021 | 257 | 0.810 |
Why?
| | Intubation, Intratracheal | 3 | 2019 | 225 | 0.810 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2019 | 99 | 0.800 |
Why?
| | Child, Preschool | 32 | 2022 | 9448 | 0.760 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 231 | 0.720 |
Why?
| | Nutritional Support | 1 | 2017 | 28 | 0.630 |
Why?
| | Echocardiography, Doppler | 3 | 2018 | 94 | 0.620 |
Why?
| | Respiratory Tract Diseases | 1 | 2019 | 142 | 0.610 |
Why?
| | Gestational Age | 7 | 2021 | 765 | 0.600 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 98 | 0.600 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2013 | 48 | 0.560 |
Why?
| | Male | 53 | 2023 | 57479 | 0.560 |
Why?
| | Coinfection | 3 | 2022 | 119 | 0.550 |
Why?
| | Female | 56 | 2023 | 61268 | 0.550 |
Why?
| | Risk Factors | 20 | 2022 | 8958 | 0.540 |
Why?
| | Patient Discharge | 10 | 2023 | 791 | 0.540 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2015 | 10 | 0.530 |
Why?
| | Energy Intake | 1 | 2017 | 445 | 0.510 |
Why?
| | Adolescent | 33 | 2023 | 18364 | 0.490 |
Why?
| | Nitric Oxide | 6 | 2022 | 891 | 0.490 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2014 | 15 | 0.490 |
Why?
| | Paramyxoviridae Infections | 1 | 2013 | 10 | 0.480 |
Why?
| | Chlorides | 3 | 2020 | 137 | 0.480 |
Why?
| | Metapneumovirus | 1 | 2013 | 12 | 0.480 |
Why?
| | Retrospective Studies | 26 | 2023 | 12932 | 0.470 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 105 | 0.460 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 124 | 0.460 |
Why?
| | Aftercare | 4 | 2022 | 194 | 0.460 |
Why?
| | Myocardial Contraction | 1 | 2015 | 338 | 0.460 |
Why?
| | Bacteria | 4 | 2022 | 751 | 0.440 |
Why?
| | Pulmonary Embolism | 2 | 2012 | 182 | 0.430 |
Why?
| | Peripheral Vascular Diseases | 1 | 2013 | 98 | 0.430 |
Why?
| | Patient Readmission | 2 | 2018 | 631 | 0.430 |
Why?
| | Energy Metabolism | 1 | 2017 | 762 | 0.430 |
Why?
| | Lung Diseases | 2 | 2010 | 709 | 0.420 |
Why?
| | Oxygen | 3 | 2019 | 854 | 0.420 |
Why?
| | Bacterial Infections | 3 | 2023 | 226 | 0.420 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 468 | 0.410 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 233 | 0.410 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 3 | 0.410 |
Why?
| | Embolectomy | 1 | 2011 | 10 | 0.400 |
Why?
| | Bereavement | 2 | 2021 | 49 | 0.390 |
Why?
| | Influenza A virus | 3 | 2020 | 90 | 0.380 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 374 | 0.380 |
Why?
| | Acute Kidney Injury | 4 | 2021 | 705 | 0.370 |
Why?
| | Wilms Tumor | 1 | 2011 | 68 | 0.370 |
Why?
| | Milrinone | 2 | 2021 | 27 | 0.370 |
Why?
| | Pulmonary Artery | 3 | 2011 | 1055 | 0.370 |
Why?
| | Vasodilator Agents | 3 | 2021 | 328 | 0.360 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1433 | 0.360 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2020 | 29 | 0.340 |
Why?
| | Coronary Care Units | 2 | 2018 | 14 | 0.330 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 191 | 0.320 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 86 | 0.320 |
Why?
| | Infant, Extremely Premature | 2 | 2020 | 57 | 0.320 |
Why?
| | Quality of Life | 11 | 2023 | 2355 | 0.320 |
Why?
| | Sulfones | 1 | 2008 | 98 | 0.320 |
Why?
| | Multiple Organ Failure | 3 | 2023 | 120 | 0.320 |
Why?
| | Hernia, Diaphragmatic | 1 | 2008 | 68 | 0.310 |
Why?
| | Logistic Models | 6 | 2019 | 1896 | 0.310 |
Why?
| | Quality Improvement | 3 | 2022 | 962 | 0.300 |
Why?
| | Heart Diseases | 2 | 2023 | 340 | 0.300 |
Why?
| | Administration, Inhalation | 5 | 2022 | 652 | 0.300 |
Why?
| | Health Resources | 4 | 2022 | 130 | 0.300 |
Why?
| | Cohort Studies | 13 | 2022 | 5078 | 0.300 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 241 | 0.300 |
Why?
| | Staphylococcus | 2 | 2017 | 68 | 0.300 |
Why?
| | Kidney Neoplasms | 1 | 2011 | 333 | 0.300 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 348 | 0.290 |
Why?
| | Metagenomics | 4 | 2023 | 134 | 0.280 |
Why?
| | Piperazines | 1 | 2008 | 316 | 0.280 |
Why?
| | Follow-Up Studies | 8 | 2021 | 4575 | 0.270 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2008 | 189 | 0.270 |
Why?
| | Hospital Mortality | 8 | 2023 | 811 | 0.270 |
Why?
| | Brain Injuries, Traumatic | 2 | 2021 | 310 | 0.260 |
Why?
| | Length of Stay | 4 | 2020 | 1027 | 0.260 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1514 | 0.260 |
Why?
| | Biomarkers | 8 | 2023 | 3568 | 0.250 |
Why?
| | Diastole | 3 | 2019 | 145 | 0.250 |
Why?
| | Pregnancy | 9 | 2022 | 5671 | 0.250 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 14 | 0.240 |
Why?
| | Time Factors | 9 | 2020 | 6368 | 0.240 |
Why?
| | DEAD Box Protein 58 | 2 | 2022 | 8 | 0.240 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 37 | 0.240 |
Why?
| | Tunica Intima | 1 | 2004 | 77 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2004 | 455 | 0.230 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2491 | 0.230 |
Why?
| | Epinephrine | 2 | 2022 | 166 | 0.230 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 145 | 0.220 |
Why?
| | Age Factors | 6 | 2021 | 2990 | 0.220 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2022 | 17 | 0.220 |
Why?
| | Receptors, Immunologic | 2 | 2022 | 206 | 0.220 |
Why?
| | Cotinine | 1 | 2023 | 76 | 0.220 |
Why?
| | Treatment Outcome | 11 | 2022 | 9319 | 0.210 |
Why?
| | Wounds and Injuries | 2 | 2021 | 697 | 0.210 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2022 | 11 | 0.210 |
Why?
| | Hypotension | 1 | 2023 | 119 | 0.210 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2004 | 236 | 0.210 |
Why?
| | Protein Kinases | 1 | 2004 | 306 | 0.210 |
Why?
| | Central Venous Catheters | 1 | 2022 | 42 | 0.210 |
Why?
| | Smoke | 1 | 2023 | 137 | 0.200 |
Why?
| | Parents | 4 | 2021 | 1208 | 0.200 |
Why?
| | Central Venous Pressure | 1 | 2021 | 13 | 0.200 |
Why?
| | Prone Position | 1 | 2021 | 31 | 0.200 |
Why?
| | Capnography | 1 | 2021 | 12 | 0.200 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2022 | 61 | 0.200 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2022 | 119 | 0.190 |
Why?
| | United States | 11 | 2022 | 12496 | 0.190 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2021 | 41 | 0.190 |
Why?
| | Common Data Elements | 1 | 2020 | 9 | 0.190 |
Why?
| | ADAMTS4 Protein | 1 | 2020 | 15 | 0.190 |
Why?
| | Patient Positioning | 1 | 2021 | 49 | 0.190 |
Why?
| | Iloprost | 1 | 2021 | 46 | 0.190 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1122 | 0.190 |
Why?
| | Communicable Diseases | 1 | 2022 | 132 | 0.190 |
Why?
| | Multiple Trauma | 1 | 2021 | 88 | 0.190 |
Why?
| | Pregnancy in Diabetics | 1 | 2022 | 88 | 0.190 |
Why?
| | Shock | 1 | 2022 | 91 | 0.190 |
Why?
| | Catheterization, Central Venous | 1 | 2022 | 95 | 0.190 |
Why?
| | Thoracic Injuries | 1 | 2021 | 62 | 0.190 |
Why?
| | Spinal Injuries | 1 | 2021 | 51 | 0.190 |
Why?
| | Vasopressins | 1 | 2021 | 64 | 0.190 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 333 | 0.190 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 69 | 0.190 |
Why?
| | Extremities | 1 | 2021 | 112 | 0.190 |
Why?
| | Young Adult | 9 | 2022 | 10731 | 0.190 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 618 | 0.180 |
Why?
| | Epoprostenol | 1 | 2021 | 132 | 0.180 |
Why?
| | Angiogenic Proteins | 1 | 2020 | 20 | 0.180 |
Why?
| | Abdominal Injuries | 1 | 2021 | 117 | 0.180 |
Why?
| | Radiography, Thoracic | 1 | 2021 | 163 | 0.180 |
Why?
| | Caregivers | 3 | 2021 | 709 | 0.180 |
Why?
| | Morbidity | 4 | 2022 | 293 | 0.180 |
Why?
| | Medical Audit | 1 | 2020 | 75 | 0.180 |
Why?
| | Multivariate Analysis | 4 | 2018 | 1469 | 0.180 |
Why?
| | Mannose-Binding Lectin | 1 | 2019 | 21 | 0.170 |
Why?
| | Medical Records | 1 | 2020 | 160 | 0.170 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2020 | 80 | 0.170 |
Why?
| | Medicine | 1 | 2020 | 106 | 0.170 |
Why?
| | Nervous System Diseases | 1 | 2022 | 261 | 0.170 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 119 | 0.170 |
Why?
| | Pulmonary Circulation | 2 | 2015 | 423 | 0.170 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 458 | 0.170 |
Why?
| | CRISPR-Cas Systems | 1 | 2019 | 86 | 0.170 |
Why?
| | Cardiotonic Agents | 1 | 2019 | 127 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2020 | 2856 | 0.160 |
Why?
| | Drug Resistance, Bacterial | 1 | 2019 | 155 | 0.160 |
Why?
| | Adult | 10 | 2024 | 31327 | 0.160 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 25 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2262 | 0.160 |
Why?
| | Proteomics | 3 | 2020 | 850 | 0.160 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 284 | 0.160 |
Why?
| | Calorimetry, Indirect | 1 | 2017 | 72 | 0.160 |
Why?
| | Hospitalization | 4 | 2023 | 1778 | 0.160 |
Why?
| | Academic Medical Centers | 2 | 2017 | 422 | 0.160 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 70 | 0.150 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 38 | 0.150 |
Why?
| | Chorioamnionitis | 1 | 2017 | 37 | 0.150 |
Why?
| | Blood Pressure | 4 | 2023 | 1656 | 0.150 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 73 | 0.150 |
Why?
| | Respiratory System | 1 | 2018 | 141 | 0.150 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 68 | 0.150 |
Why?
| | Motivation | 1 | 2021 | 502 | 0.150 |
Why?
| | Inservice Training | 1 | 2018 | 103 | 0.150 |
Why?
| | Mutation, Missense | 1 | 2019 | 300 | 0.150 |
Why?
| | Delirium | 1 | 2018 | 68 | 0.150 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 199 | 0.150 |
Why?
| | Toll-Like Receptor 4 | 1 | 2020 | 330 | 0.150 |
Why?
| | Research Design | 3 | 2020 | 961 | 0.150 |
Why?
| | Glasgow Coma Scale | 3 | 2022 | 146 | 0.150 |
Why?
| | Heart Failure | 2 | 2021 | 1967 | 0.150 |
Why?
| | Dysbiosis | 1 | 2018 | 148 | 0.150 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 482 | 0.150 |
Why?
| | Chronic Disease | 3 | 2022 | 1631 | 0.140 |
Why?
| | Pneumonia | 1 | 2022 | 579 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 178 | 0.140 |
Why?
| | Hemodynamics | 3 | 2023 | 1002 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 418 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 449 | 0.140 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 100 | 0.140 |
Why?
| | Observer Variation | 1 | 2017 | 306 | 0.140 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 125 | 0.140 |
Why?
| | Fibroblasts | 1 | 2020 | 835 | 0.140 |
Why?
| | MicroRNAs | 1 | 2022 | 633 | 0.140 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 19 | 0.140 |
Why?
| | Delphi Technique | 3 | 2020 | 163 | 0.130 |
Why?
| | Mothers | 2 | 2022 | 675 | 0.130 |
Why?
| | Needs Assessment | 1 | 2017 | 325 | 0.130 |
Why?
| | Organ Dysfunction Scores | 3 | 2020 | 39 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2019 | 313 | 0.130 |
Why?
| | Computational Biology | 1 | 2019 | 541 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2659 | 0.130 |
Why?
| | Pre-Eclampsia | 1 | 2017 | 183 | 0.130 |
Why?
| | Indiana | 1 | 2015 | 29 | 0.130 |
Why?
| | Medical Informatics | 1 | 2016 | 97 | 0.130 |
Why?
| | Hypokalemia | 1 | 2014 | 31 | 0.130 |
Why?
| | Trauma Centers | 3 | 2022 | 376 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2019 | 347 | 0.120 |
Why?
| | Bronchiolitis, Viral | 1 | 2013 | 10 | 0.120 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 369 | 0.120 |
Why?
| | Metabolomics | 1 | 2018 | 540 | 0.120 |
Why?
| | Birth Weight | 1 | 2017 | 463 | 0.120 |
Why?
| | Hospitals, Pediatric | 3 | 2023 | 504 | 0.120 |
Why?
| | Schools, Medical | 1 | 2015 | 138 | 0.120 |
Why?
| | Patient Care Team | 1 | 2018 | 521 | 0.110 |
Why?
| | Signal Transduction | 2 | 2020 | 4688 | 0.110 |
Why?
| | Smoking | 2 | 2018 | 1478 | 0.110 |
Why?
| | Hypertension | 2 | 2019 | 1199 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 760 | 0.110 |
Why?
| | Colorado | 4 | 2017 | 4178 | 0.110 |
Why?
| | Risk Assessment | 5 | 2018 | 3043 | 0.110 |
Why?
| | Nasopharynx | 2 | 2023 | 64 | 0.110 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 43 | 0.110 |
Why?
| | Physicians | 1 | 2021 | 792 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2012 | 78 | 0.110 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 168 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2413 | 0.100 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 29 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 354 | 0.100 |
Why?
| | Risk | 2 | 2012 | 849 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 700 | 0.100 |
Why?
| | Polysaccharides | 1 | 2012 | 77 | 0.100 |
Why?
| | Carbon Dioxide | 2 | 2023 | 230 | 0.100 |
Why?
| | Abbreviated Injury Scale | 2 | 2021 | 21 | 0.100 |
Why?
| | Enoxaparin | 1 | 2012 | 51 | 0.100 |
Why?
| | Suction | 1 | 2011 | 31 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 465 | 0.100 |
Why?
| | Bacterial Load | 1 | 2011 | 61 | 0.100 |
Why?
| | Grief | 2 | 2021 | 35 | 0.100 |
Why?
| | Immunomodulation | 1 | 2012 | 89 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1031 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2012 | 286 | 0.100 |
Why?
| | Pressure | 2 | 2023 | 226 | 0.100 |
Why?
| | Anticoagulants | 2 | 2012 | 555 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2017 | 1048 | 0.100 |
Why?
| | RNA, Ribosomal | 1 | 2011 | 158 | 0.100 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 166 | 0.100 |
Why?
| | Interferons | 2 | 2022 | 151 | 0.100 |
Why?
| | Metagenome | 1 | 2011 | 120 | 0.100 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 227 | 0.090 |
Why?
| | Ultrasonography | 1 | 2015 | 714 | 0.090 |
Why?
| | RNA, Bacterial | 1 | 2011 | 177 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 233 | 0.090 |
Why?
| | Fetal Blood | 1 | 2012 | 270 | 0.090 |
Why?
| | Survival Rate | 3 | 2019 | 1716 | 0.090 |
Why?
| | Vitamin D | 1 | 2013 | 352 | 0.090 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 42 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2433 | 0.090 |
Why?
| | Blood Glucose | 2 | 2019 | 1936 | 0.090 |
Why?
| | Stakeholder Participation | 2 | 2020 | 70 | 0.090 |
Why?
| | Antihypertensive Agents | 1 | 2013 | 436 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1787 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 734 | 0.090 |
Why?
| | Influenza Vaccines | 1 | 2014 | 501 | 0.080 |
Why?
| | Survivors | 2 | 2022 | 411 | 0.080 |
Why?
| | Sildenafil Citrate | 1 | 2008 | 57 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 4684 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3169 | 0.080 |
Why?
| | Pediatrics | 1 | 2016 | 980 | 0.080 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2008 | 65 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2018 | 2230 | 0.080 |
Why?
| | Stroke Volume | 2 | 2021 | 513 | 0.080 |
Why?
| | Purines | 1 | 2008 | 160 | 0.080 |
Why?
| | Pulmonary Edema | 1 | 2008 | 119 | 0.080 |
Why?
| | Stem Cells | 1 | 2012 | 556 | 0.080 |
Why?
| | Transcriptome | 2 | 2023 | 752 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 980 | 0.070 |
Why?
| | Prognosis | 3 | 2018 | 3425 | 0.070 |
Why?
| | Diseases in Twins | 1 | 2008 | 181 | 0.070 |
Why?
| | Survival Analysis | 2 | 2022 | 1262 | 0.070 |
Why?
| | Gene Expression | 2 | 2022 | 1482 | 0.070 |
Why?
| | Clinical Competence | 2 | 2023 | 950 | 0.070 |
Why?
| | Phenotype | 2 | 2023 | 2937 | 0.070 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 181 | 0.070 |
Why?
| | Cell Division | 2 | 2004 | 775 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2004 | 41 | 0.060 |
Why?
| | Cytokines | 1 | 2012 | 1880 | 0.060 |
Why?
| | Chromones | 1 | 2004 | 37 | 0.060 |
Why?
| | Aorta | 2 | 2004 | 364 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 541 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1046 | 0.060 |
Why?
| | Carotid Artery Injuries | 1 | 2004 | 42 | 0.060 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 67 | 0.060 |
Why?
| | Syndecan-1 | 1 | 2023 | 30 | 0.060 |
Why?
| | Disaccharides | 1 | 2023 | 18 | 0.060 |
Why?
| | Androstadienes | 1 | 2004 | 95 | 0.060 |
Why?
| | Oligonucleotides, Antisense | 1 | 2004 | 99 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2023 | 42 | 0.060 |
Why?
| | Glycocalyx | 1 | 2023 | 23 | 0.060 |
Why?
| | Water-Electrolyte Balance | 1 | 2023 | 29 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 35 | 0.060 |
Why?
| | Probability | 1 | 2004 | 302 | 0.060 |
Why?
| | Morpholines | 1 | 2004 | 106 | 0.060 |
Why?
| | Hyperoxia | 1 | 2004 | 97 | 0.060 |
Why?
| | Catheterization | 1 | 2004 | 164 | 0.060 |
Why?
| | Proteoglycans | 1 | 2023 | 109 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2004 | 143 | 0.060 |
Why?
| | Methicillin | 1 | 2022 | 12 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 142 | 0.060 |
Why?
| | Vascular Resistance | 1 | 2004 | 356 | 0.060 |
Why?
| | Chemotactic Factors | 1 | 2022 | 51 | 0.050 |
Why?
| | Sirolimus | 1 | 2004 | 195 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 526 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2022 | 2057 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2022 | 45 | 0.050 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 255 | 0.050 |
Why?
| | RNA, Viral | 2 | 2017 | 568 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 50 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 341 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 418 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 408 | 0.050 |
Why?
| | Neonatologists | 1 | 2021 | 3 | 0.050 |
Why?
| | Norepinephrine | 1 | 2022 | 212 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 37 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 369 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2004 | 2434 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 410 | 0.050 |
Why?
| | Influenza in Birds | 1 | 2020 | 4 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2022 | 160 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 1795 | 0.050 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 76 | 0.050 |
Why?
| | Blood Gas Analysis | 1 | 2020 | 69 | 0.050 |
Why?
| | Stromal Cells | 1 | 2020 | 100 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 817 | 0.050 |
Why?
| | Birds | 1 | 2020 | 80 | 0.050 |
Why?
| | Bicarbonates | 1 | 2020 | 44 | 0.050 |
Why?
| | Hematoma, Subdural | 1 | 2019 | 17 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2020 | 69 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 971 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2021 | 313 | 0.040 |
Why?
| | Skull Fractures | 1 | 2019 | 30 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 249 | 0.040 |
Why?
| | Phosphorylation | 1 | 2004 | 1622 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2021 | 500 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 44 | 0.040 |
Why?
| | Child Health | 1 | 2020 | 136 | 0.040 |
Why?
| | Cardiac Output | 1 | 2019 | 147 | 0.040 |
Why?
| | Intracranial Hemorrhages | 1 | 2019 | 77 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 735 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 186 | 0.040 |
Why?
| | Maternal Exposure | 2 | 2012 | 140 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 111 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 394 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 344 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 600 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2020 | 191 | 0.040 |
Why?
| | American Heart Association | 1 | 2020 | 270 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 517 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3156 | 0.040 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 142 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 984 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 275 | 0.040 |
Why?
| | Seasons | 1 | 2020 | 461 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 533 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 341 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2021 | 245 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 808 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 261 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5339 | 0.040 |
Why?
| | Hypoxia | 1 | 2004 | 957 | 0.040 |
Why?
| | Animals | 5 | 2020 | 33152 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1405 | 0.040 |
Why?
| | Mortality | 1 | 2020 | 297 | 0.040 |
Why?
| | Data Collection | 1 | 2020 | 652 | 0.040 |
Why?
| | Creatinine | 1 | 2019 | 491 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2017 | 75 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 252 | 0.040 |
Why?
| | Causality | 1 | 2017 | 109 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1590 | 0.040 |
Why?
| | Homozygote | 1 | 2017 | 189 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2020 | 444 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2019 | 746 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1379 | 0.040 |
Why?
| | Calcium | 1 | 2022 | 1151 | 0.040 |
Why?
| | Family | 1 | 2020 | 578 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2018 | 146 | 0.040 |
Why?
| | Social Class | 1 | 2018 | 217 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2017 | 345 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 545 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2004 | 4044 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 110 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 545 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 817 | 0.030 |
Why?
| | Communication | 1 | 2021 | 754 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1516 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2657 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1159 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 935 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 923 | 0.030 |
Why?
| | Potassium | 1 | 2014 | 132 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 653 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1338 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2014 | 37 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1857 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 177 | 0.030 |
Why?
| | Aged | 2 | 2022 | 19599 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 1969 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1196 | 0.030 |
Why?
| | Depression | 1 | 2021 | 1133 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1237 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2545 | 0.030 |
Why?
| | Immune System | 1 | 2013 | 181 | 0.030 |
Why?
| | Algorithms | 1 | 2019 | 1522 | 0.030 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 161 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1701 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 294 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2013 | 468 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 555 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 504 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1072 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2477 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 717 | 0.020 |
Why?
| | Global Health | 1 | 2008 | 309 | 0.020 |
Why?
| | Mice | 1 | 2020 | 15446 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 27514 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 219 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 541 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3358 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|